GSK to Acquire Sitari Pharmaceuticals for its Celiac Diseases Program

 GSK to Acquire Sitari Pharmaceuticals for its Celiac Diseases Program

GSK to Acquire Sitari Pharmaceuticals for its Celiac Diseases Program

Shots:

  • GSK signs an agreement with Avalon Ventures to acquire Sitari Pharmaceutical with its all intellectual property rights and obtain transglutaminase 2 small molecule program for celiac disease
  • In Apr’2013, GSK collaborated with Avalon to fund and launch up to ten life science companies, Sitari is the first company under the alliance incubated at COI Pharmaceutical, having a preclinical program focusing on Celiac diseases
  • Sitari’s TG2 inhibitors trigger the inflammatory cascade in response to gluten exposure and have the potential to suppress the autoimmune response resulting in intestinal inflammation and cell pathogenesis patients with celiac disease

Click here to­ read full press release/ article | Ref: Business Wire | Image: COI Pharmaceuticals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post